RNS Number : 1049G
Porvair PLC
17 July 2023
 

FOR IMMEDIATE RELEASE                                                                              17 July 2023

 

porvair logo

 

Porvair plc

("Porvair" or the "Group" or the "Company")

 

Acquisition completion

 

Porvair plc ("Porvair" or the "Group"), the specialist filtration, laboratory and environmental technology group, announces that on 14 July 2023 it completed its acquisition of 100% of the issued share capital of two businesses, Ratiolab GmbH and Ratiolab Kft. (together "Ratiolab"), following receipt of Hungarian regulatory approval.

 

As previously announced, Ratiolab GmbH, located outside Frankfurt, sells a wide range of laboratory consumables in Europe and the Middle East. Ratiolab Kft., located close to Budapest, manufactures laboratory consumables in an 8,000m2 facility, the freehold of which is included in the acquisition. Ratiolab has annual external revenues of around €12 million. The transaction is expected to be earnings neutral (after acquisition costs) in 2023, and earnings enhancing thereafter.

 

The Board believes Ratiolab will fit well into the Group's Laboratory division, offering a complementary product range and adding European manufacturing capabilities, injection moulding expertise, and routes to market.

 

For further information, please contact:

 

Porvair plc

01553 765 500

Ben Stocks, Group Chief Executive

James Mills, Group Finance Director




Buchanan Communications

0207 466 5000

Charles Ryland / Simon Compton / Jack Devoy


 

Notes to Editors

Porvair is a group of specialist filtration, laboratory and environmental technology businesses.  Its businesses design and manufacture a range of bespoke consumable filtration products that are used in a range of niche filtration markets.  It operates in three divisions: Aerospace & Industrial; Laboratory; and Metal Melt Quality.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQSFWFFLEDSELW